SCHEMBL5162046

SCHEMBL5162046

CC(C)(C)OC(=O)CC(=O)c1cocn1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 1/20 0.36
CCNE2 O96020 1/20 0.36
CDK1 P06493 1/20 0.36
CDK4 P11802 1/20 0.36
CCNB1 P14635 1/20 0.36
CCND1 P24385 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
ACACB O00763 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PIK3CD O00329 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
F2R P25116 1/20 0.31
RIPK1 Q13546 1/20 0.31
IMPDH2 P12268 1/20 0.30
IMPDH1 P20839 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160077 0.83 ACACB (0.38) ACACBKDM4EALDH1A1PIK3CDF2R
SCHEMBL5163521 0.79 MGAM (0.44) CCNB2CCNE2CDK1CDK4CCNB1
SCHEMBL19438494 0.76 PIK3CD (0.37) ACACBPIK3CDF2R
SCHEMBL6165060 0.74 SCN9A (0.41) ACACBL3MBTL1GPR119IMPDH2IMPDH1
SCHEMBL3821418 0.73 MAPT (0.46) ALDH1A1
SCHEMBL5161432 0.73 L3MBTL1 (0.38) CCNB2CCNE2CDK1CDK4CCNB1
SCHEMBL2632662 0.72
SCHEMBL5158131 0.72 SMN1; SMN2 (0.48) KDM4EALDH1A1L3MBTL1
SCHEMBL14740765 0.72 KDM4E (0.48) KDM4E
SCHEMBL20797220 0.71 PIK3CD (0.36) ACACBALDH1A1PIK3CDF2RIMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO CCNB2 3857/4885CCNE2 4158/4885CDK1 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.